ReviewDiagnostics (Basel, Switzerland)2022
Immunoinformatics Approach for Epitope-Based Vaccine Design: Key Steps for Breast Cancer Vaccine.
Review in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Structural Assessment of Fibrillated Beta Amyloid to Reveal the Potential Epitopes for Alzheimer's Disease.Cell biochemistry and biophysics · 2026Article
- Article
- Identification and evaluation of tumor pyroptosis-associated antigens for design a vaccine candidate against lung cancer.Scientific reports · 2026Article
- Integrative Spatial Transcriptomics and Immunoinformatics for Prognostic Multi-Epitope Vaccine Construct Prediction Against Synovial Sarcoma.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Advances in linear epitope-based subunit vaccines powered by artificial intelligence: current status and challenges.Frontiers in immunology · 2026Review
- Immunoinformatic-guided design of a polo-like kinase 1 (PLK1)-targeted multi-epitope vaccine with preliminaryFrontiers in bioinformatics · 2026Article
- Targeting SOX9: designing a novel vaccine against triple-negative breast cancer.Scientific reports · 2025Article
- Bioinformatics analysis of innovative multi-epitope vaccine utilizing MAGE-A, MAM-A, and Gal-3 for breast cancer management.Scientific reports · 2025Article
- Deep Clustering-Based Immunotherapy Prediction for Gastric Cancer mRNA Vaccine Development.International journal of molecular sciences · 2025Article
- Bioinformatics analysis of the in silico engineered protein vaccine with and without Escherichia coli heat labile enterotoxin adjuvant on the model of Klebsiella pneumoniae.Scientific reports · 2025Article
- Unveiling reverse vaccinology and immunoinformatics toward Saint Louis encephalitis virus: a ray of hope for vaccine development.Frontiers in immunology · 2025Article
- Screening of Oncogenic Proteins and Development of a Multiepitope Peptide Vaccine Targeting AKT1 and PARP1 for Breast Cancer by Integrating Reverse Vaccinology and Immune-Informatics Approaches.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Article
- Innovative Immunoinformatics Tools for Enhancing MHC (Major Histocompatibility Complex) Class I Epitope Prediction in Immunoproteomics.Protein and peptide letters · 2025Review
- Article
- VaxOptiML: leveraging machine learning for accurate prediction of MHC-I and II epitopes for optimized cancer immunotherapy.Immunogenetics · 2024Article
- Reverse Vaccinology Integrated with Biophysics Techniques for Designing a Peptide-Based Subunit Vaccine for Bourbon Virus.Bioengineering (Basel, Switzerland) · 2024Article
- Article
- Peptide Vaccines as Therapeutic and Prophylactic Agents for Female-Specific Cancers: The Current Landscape.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Design and In Silico Validation of a Novel MZF-1-Based Multi-Epitope Vaccine to Combat Metastatic Triple Negative Breast Cancer.Vaccines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccines are an upcoming medical intervention for breast cancer. By targeting the tumor antigen, cancer vaccines can be designed to train the immune system to recognize tumor cells. Therefore, along with technological advances, the vaccine design process is now starting to be carried out with more rational methods such as designing epitope-based peptide vaccines using immunoinformatics methods. Immunoinformatics methods can assist vaccine design in terms of antigenicity and safety. Common protocols used to design epitope-based peptide vaccines include tumor antigen identification, protein structure analysis, T cell epitope prediction, epitope characterization, and evaluation of protein-epitope interactions. Tumor antigen can be divided into two types: tumor associated antigen and tumor specific antigen. We will discuss the identification of tumor antigens using high-throughput technologies. Protein structure analysis comprises the physiochemical, hydrochemical, and antigenicity of the protein. T cell epitope prediction models are widely available with various prediction parameters as well as filtering tools for the prediction results. Epitope characterization such as allergenicity and toxicity can be done in silico as well using allergenicity and toxicity predictors. Evaluation of protein-epitope interactions can also be carried out in silico with molecular simulation. We will also discuss current and future developments of breast cancer vaccines using an immunoinformatics approach. Finally, although prediction models have high accuracy, the opposite can happen after being tested in vitro and in vivo. Therefore, further studies are needed to ensure the effectiveness of the vaccine to be developed. Although epitope-based peptide vaccines have the disadvantage of low immunogenicity, the addition of adjuvants can be a solution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.